
160 jobs in peril at BMS Ireland plant
pharmafile | March 7, 2014 | News story | Manufacturing and Production, Sales and Marketing | BMS, Cruiserath, Dublin, Ireland, swords
Bristol-Myers Squibb will close its Dublin manufacturing facility at Cruiserath in Ireland by the end of 2015 the firm has announced.
The development will mean 130 workers at the plant will lose their jobs, according to a statement from the US company this week. Local reports say that a further 30 jobs are expected to go at BMS’ Swords site, which is also based in Ireland.
The company, like so many in big pharma over the past five years, is making the cuts due to a ‘changing market demand’. But BMS says that it ‘remains committed’ to its Swords facility which currently employs 320 staff, and is not looking to cut close that site.
General manager of API operations Ireland Susan Hynes, said: ’Bristol-Myers Squibb has a long history in Ireland and the company’s presence here plays an important role in the BMS global manufacturing network.”
She added: “The company is working with IDA Ireland to explore potential future uses of the Cruiserath facility and will endeavour to minimise job losses in Ireland.”
Ben Adams
Related Content

Smurfit Westrock unveils new clinical packaging facility at Dublin Airport
Smurfit Westrock has inaugurated the first-of-its-kind adherence and clinical packaging facility, reinforcing Ireland’s role at …

Elekta and BMS partner for digital treatment for melanoma
Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan …

BMS acquires Mirati Therapeutics for $4.8bn
Bristol Myers Squibb (BMS) and Mirati Therapeutics have announced that they have entered into a …






